Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/17/2018 | 02:31pm CEST

NOVATO, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has expanded its leadership team with the appointment of Wladimir (Vlad) Hogenhuis, M.D., as Chief Operating Officer, effective September 28, 2018. In this newly created role, Dr. Hogenhuis will oversee Global Commercial Operations, Business Development and Technical Operations functions. He will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx’s Chief Executive Officer, and will serve on the Executive Leadership Team. Dr. Hogenhuis joins Ultragenyx from GlaxoSmithKline (GSK), where he most recently served as Senior Vice President and General Manager, Specialty Franchise.

“Vlad has tremendous global cross-functional experience, and a track record of driving growth, building and leading multi-national teams,” said Dr. Kakkis. “We welcome him to Ultragenyx and believe his leadership and expertise will help us continue to build and manage our rapidly growing global operations to manufacture and commercialize our products and pipeline, maximizing their potential. Vlad’s strong medical and business background provides the high quality insight and experience needed to help Ultragenyx achieve its ambitious goals with its multi-mode product portfolio. I look forward to working with Vlad for many years to come.”

“Ultragenyx is a company that is making great strides in translating science into therapies that make a meaningful difference in the lives of patients with rare diseases, and I look forward to joining the company at this pivotal time,” said Dr. Hogenhuis.

Dr. Hogenhuis is a 24-year veteran of the pharmaceutical industry. He spent the last six years at GSK, where he was initially responsible for the company's Cardiovascular, Metabolic and Neurosciences Franchise, and later led the Specialty Franchise. At GSK he had strategic responsibility and commercial accountability for novel medicines for lupus disease, type II diabetes, and rheumatoid arthritis, with six phase 3 compounds in rheumatology, oncology, dermatology, and nephrology.  He was also responsible for the integration of manufacturing and research in shaping product launches in therapeutic areas new to GSK. Prior to GSK, Dr. Hogenhuis spent 18 years at Merck & Co. in a variety of leadership and operational roles including General Manager for the Neuroscience, Dermatology & Ophthalmology U.S. Operations,  General Manager of Belgium and Luxemburg, and Head of Marketing in China with responsibility for all of Merck’s products.

Dr. Hogenhuis has a Medical Degree Cum Laude from Leiden University in the Netherlands and an MBA degree from the Wharton School of Business. He served as a National Institutes of Health Fellow in Medical Decision Making at Tufts Medical Center in Boston, and as a Surgeon Lieutenant in the Royal Dutch Navy.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the Company's website at www.ultragenyx.com.

Contact:
Ultragenyx Pharmaceutical Inc.
Investors & Media
Danielle Keatley
415-475-6876
dkeatley@ultragenyx.com

Ultragenyx Pharmaceutical Inc. Logo


© GlobeNewswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
10/09FDA, EMA to review Novartis' siponimod for secondary progressive MS
AQ
10/01ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/27ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/27Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinica..
GL
09/26ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/19ULTRAGENYX PHARMACEUTICAL : Expands Leadership Team and Appoints Dr. Wladimir Ho..
AQ
09/19ULTRAGENYX PHARMACEUTICAL : appoints Dr. Wladimir Hogenhuis as COO
AQ
09/17ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers, Fina..
AQ
09/17Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chi..
GL
08/30Ultragenyx to Present at Upcoming Investor Conferences
GL
More news
News from SeekingAlpha
09/27Ultragenyx's DTX301 shows positive effect in OTC study 
09/17Ultragenyx appoints Dr. Wladimir Hogenhuis as COO 
09/10Premarket analyst action - healthcare 
09/05Gene therapy players under pressure 
08/29YOUR DAILY PHARMA SCOOP : ESPR Phase 3 Positive, FDA Rejects Volanesorsen, Ozemp.. 
Financials ($)
Sales 2018 56,1 M
EBIT 2018 -390 M
Net income 2018 -227 M
Finance 2018 255 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 53,3x
EV / Sales 2019 28,1x
Capitalization 3 249 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 84,8 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC33.23%3 249
GILEAD SCIENCES1.59%95 398
VERTEX PHARMACEUTICALS20.99%46 338
REGENERON PHARMACEUTICALS2.18%40 777
NEUROCRINE BIOSCIENCES, INC.41.84%10 086
SAREPTA THERAPEUTICS INC136.05%8 671